Publications by authors named "John P Farrant"
Article Synopsis
- Hypertrophic cardiomyopathy (HCM) is a diverse heart condition that can lead to severe health issues and traditionally managed through symptom relief and the use of defibrillators to prevent sudden cardiac death.
- There is a recognized need for treatments that modify the disease itself, and recently, new therapies like mavacamten, a myosin inhibitor, have gained regulatory approval.
- Clinical trials for HCM face unique challenges, which include selecting patients based on their genetic and symptom profiles, measuring outcomes effectively, and considering factors like trial duration and sample size when interpreting results.
Article Synopsis
- - This study focused on classifying patients with heart failure (HF) and preserved or mildly reduced ejection fraction into specific phenogroups to improve targeted treatment options.
- - Researchers analyzed data from over 2,000 patients across five UK hospitals using advanced machine learning techniques and found three distinct phenogroups, each with different clinical traits and survival outcomes.
- - The findings revealed that survival rates declined from the first phenogroup to the third, highlighting the importance of phenogroup membership in predicting survival better than traditional factors, though it did not predict hospitalisation for HF.
Aims: Population-wide, person-level, linked electronic health record data are increasingly used to estimate epidemiology, guide resource allocation, and identify events in clinical trials. The accuracy of data from NHS Digital (now part of NHS England) for identifying hospitalization for heart failure (HHF), a key HF standard, is not clear. This study aimed to evaluate the accuracy of NHS Digital data for identifying HHF.
View Article and Find Full Text PDFBackground: Disturbances of copper (Cu) homeostasis can lead to hypertrophic cardiac phenotypes (eg, Wilson's disease). We previously identified abnormal Cu homeostasis in patients with hypertrophic cardiomyopathy (HCM) and, therefore, hypothesised that Cu-selective chelation with trientine dihydrochloride may slow or reverse disease progression in HCM. The aim of this study was, therefore to explore the clinical efficacy, safety and tolerability of trientine in HCM.
View Article and Find Full Text PDF